1 Global tuberculosis report 2018. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. WHO/CDS/TB/2018.20.
2 Brasil, Ministério da Saúde. Boletim Epidemiológico 2017. Secretaria de Vigilância em Saúde - Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais. Brasil, 2017.
3 Onyango DO, Yuen CM, Cain KP, Ngari F, Masini EO, Borgdorff MW. Reduction of HIV-associated excess mortality by antiretroviral treatment among tuberculosis patients in Kenya. PLoS One. 2017;12 (11):e0188235.
4 Silva DR, Muñoz-Torrico M, Duarte R, Galvão T, Bonini EH, Ferlin F, et al. Fatores de risco para tuberculose: diabetes, tabagismo, álcool e uso de outras drogas. J Bras Pneumol 2018; 44(2):145-152.
5 Parry C, Ferreira-Borges C, Poznyak V, Lönnroth K, Rehm J. The international study on alcohol and infectious diseases: three priorities for research. Addiction 2013; 108:1-2.
6 Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P, et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis 2013;13:436-48.
7 Berra TZ, Queiroz AAR, Yamamura M, Arroyo LH, Garcia MCC, Popolin MP et al. Spatial risk of tuberculosis mortality and social vulnerability in Northeast Brazil. Rev Soc Bras Med Trop 2017; 50(5):693-697.
8 Nogueira BMF, Rolla VC, Akrami KM, Kiene SM. Factors associated with tuberculosis treatment delay in patients co-infected with HIV in a high prevalence area in Brazil. PLoS ONE 2018; 13(8): e0202292.
9 Waitt CJ, Banda NPK, White SA, Kampmann B, Kumwenda J, Heyderman RS, et al. Early deaths during tuberculosis treatment are associated with depressed innate responses, bacterial infection, and tuberculosis progression. J Infect Dis 2001; 204(3):358-362.
10 Schmaltz CA, Santoro-Lopes G, Lourenço MC, Morgado MG, Velasque LS, Rolla VC. Factors impacting early mortality in tuberculosis/HIV patients: differences between subjects naïve to and previously started on HAART. PLoS One 2012;7(9):e45704.
11 Escada ROS, Velasque L, Ribeiro SR, Cardoso SW, Marins LMS, Ginsztejn E, et al. Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de Janeiro, Brazil - associated factors and causes of death. BMC Infect Dis 2017; 17: 373.
12 Seid A, Metaferia Y. Factors associated with treatment delay among newly diagnosed tuberculosis patients in Dessie city and surroundings, Northern Central Ethiopia: a cross-sectional study. BMC Public Health 2018;18(1):931-9.
13 Lee J, Nam HW, Choi SH, Yoo SS, Lee SY, Cha SI, et al. Comparison of early and late tuberculosis deaths in Korea. J Korean Med Sci 2017;32:700-703.
14 Harries AD, N J Hargreaves, F Gausi, JH Kwanjana, FM Salaniponi. High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis 2011; 5(11):1000-1005.
15 Ministério da Saúde. Recomendações para o manejo da coinfecção TB-HIV em serviços de atenção especializada a pessoas vivendo com HIV/AIDS/Ministério da Saúde. Secretaria-Executiva. Brasília: Ministério da Saúde, 2013.
16 Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Plano nacional pelo fim da tuberculose. Brasília: Ministério da Saúde; 2017.
17 Instituto Brasileiro de Geografia e Estatística. Panorama cidades. https://cidades.ibge.gov.br/brasil/pr/curitiba/panorama (acessado em 08/Nov/2018).
18 Programa das Nações Unidas para o Desenvolvimento PNUD. Instituto de pesquisa Economica Aplicada IPEA. Atlas do Desenvolvimento Humano no Brasil. http://www.atlasbrasil.org.br/2013/pt/perfil_m/curitiba_pr (acessado em 10/Nov/2018).
19 Ministério da Saúde. Secretaria de Vigilância em Saúde. Boletim Epidemiológico nº 11. mar 2018, v 44.
20 Santos DT, Nunes C, Alves LS, Queiroz AAR, Miranda M J, Arroyo LH, et al. Is there association between human development index and tuberculosis mortality risk? Evidence from a spatial analysis study in the south of Brazil. Epidemiol. and Infection 2018;1-8.
21 Guo S, Zeng D. An overview of semiparametric models in survival analysis. Journal of Stat. Plan. and Inference 2014; 151-152.
22 Ferreira JC, P CM. O que é análise de sobrevida e quando devo utilizá-la? J Bras Pneumol. 2016;42(1):77-77.
23 Glantz SA. How to analyse survival data. In: Glantz SA. Primer in Biostatistics. 7th ed. New York: McGraw-Hill Medical; 2011. p 229-44.
24 Arakawa T, Magnabosco GT, Andrade RLP, Brunello MEF, Monroe AA, Ruffino-Netto A, et al . Programa de controle da tuberculose no contexto municipal: avaliação de desempenho. Rev. Saúde Pública 2017; 51(23):1-9.
25 Loureiro RB, Villa TCS, Ruffino-Netto A, Peres RL, Braga JU, Zandonade E, et al. Acesso ao diagnóstico da tuberculose em serviços de saúde do município de Vitória, ES, Brasil. Ciênc. saúde coletiva 2014;19 (04)1233-1244.
26 Mulenga C, Mwakazanga D, Vereecken K, Khondowe S, Kapata N, Chola I, et al. Management of pulmonary tuberculosis patients in an urban setting in Zambia: a patient’s perspective. BMC Public Health 2010;10(756):1-8.
27 Bisallah CI, Rampal L, Lye MS, Mohd SS, Ibrahim N, Iliyasu Z, et al. Effectiveness of health education intervention in improving knowledge, attitude, and practices regarding Tuberculosis among HIV patients in General Hospital Minna, Nigeria - A randomized control trial. PLoS One 2018;13(2):e0192276.
28 Getahun B, Ameni G, Biadgilign S, Medhin G. Mortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia. BMC Infect Dis 2011;11(127):1-8.
29 Dizaji MK, Kazemnejad A, Tabarsi P, Zayeri F. Risk factors associated with survival of pulmonary tuberculosis. Iran J Public Health. 2018;47(7):980-987.
30 Miller TL, Wilson FA, Pang JW, Beavers S, Hoger S, Sharnprapai S, et al. Mortality hazard and survival after tuberculosis treatment. Am. Journal of Public Health 2015; 105(5): 930-7.
31 Word Health Organization. Definitions and reporting framework for tuberculosis 2013 Revision. World Health Organization; 2013.
32 Souza DCS, Oliveira KS, Andrade RLP, Scatena RM, Silva-Sobrinho RA. Aspects related to the outcomes of the treatment, in international borders, of cases of tuberculosis as associated to comorbidities. Rev. Gaúcha Enferm. 2019; 4:e20190050.
33 Imtiaz S, Shield KD, Roerecke M, Samokhvalov AV, Lönnroth K, Rehm J. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. Eur Respir J. 2017;50(1):1700216.
34 Lönnroth K, Williams B, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for tuberculosis - a systematic review. BMC Public Health 2008;8:289.
35 Rehm J, Samokhvalov AV, Neuman MG, Room R, Parry C, Lönnroth K, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health 2009;9:450.
36 Molina PE, Happel KI, Zhang P, Kolls JK, Nelson S. Focus on: Alcohol and the immune system. Alcohol Res Health. 2010;33(1-2):97-108
37 Rabahi MF, Silva Júnior JLR, Ferreira ACG, Tannus-Silva DGS, Conde MB. Tratamento da tuberculose. J Bras Pneumol. 2017;43(5):472-486.
38 Nota técnica sobre as mudanças no tratamento da tuberculose no Brasil para adultos e adolescentes. Ministério da Saúde. Brasília, 2009.